CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Cetuximab with irinotecan/FA/5-FU as first-line treatment in advanced gastro esophageal cancer: A prospective multi-center and biomarker-oriented phase II study
DOI 10.1055/s-0030-1263571
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Moehler, A Müller, T Trarbach, T Seufferlein, S Kubicka, M Geissler, F Lordick, S Daum, S Kanzler, P Galle
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
To evaluate the tolerability and efficacy of cetuximab combined with irinotecan/folinic acid/5-fluorouracil (IF) as first-line treatment in patients with advanced gastric cancer and cancer of the gastroesophageal junction. Patients and methods: Patients received weekly cetuximab (400mg/m2 day-1, subsequently 250mg/m2) plus irinotecan (80mg/m2) and a 24-hour continuous infusion of sodium folinic acid (200mg/m2) and 5…
Zitieren
Zitierempfehlung
M Moehler, A Müller, T Trarbach, T Seufferlein, S Kubicka, M Geissler, F Lordick, S Daum, S Kanzler, P Galle (2010) Cetuximab with irinotecan/FA/5-FU as first-line treatment in advanced gastro esophageal cancer: A prospective multi-center and biomarker-oriented phase II study. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263571
Mit CareLit weiterarbeiten